AMD eye drop candidate: so far, so good
Preliminary results from a Phase I trial of TargeGen's TG100801 eye drop for macular degeneration, has found it to be well tolerated in humans.
Preliminary results from a Phase I trial of TargeGen's TG100801 eye drop for macular degeneration, has found it to be well tolerated in humans at the low and high doses tested when applied topically twice daily for 14 days.
TG100801 is a small molecule, multi-target kinase inhibitor that is being developed for topical application for the treatment of macular degeneration and other debilitating diseases of the eye.
Final study results are expected by the end of April 2007 and TargeGen plans to initiate Phase II clinical trials in wet age-related macular degeneration patients by mid-2007.
Newsletter
Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.
